Statins: pros and cons
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Statins inhibit the critical step of cholesterol synthesis in which 3-hydroxy-3-methylglutaryl coenzyme A (HMGC) is transformed to mevalonate by the enzyme HMGC reductase. By doing so, they have a potent lipid-lowering effect that reduces cardiovascular risk and decreases mortality. Since the mevalonate pathway also influences endothelial function, the inflammatory response, and coagulation, the effects of statins reach well beyond their cholesterol lowering properties. As with all drugs, statins may have adverse effects; these include musculoskeletal symptoms, increased risk of diabetes, and higher rates of hemorrhagic stroke. However, the frequency of adverse effects is extremely low and, in selected patient populations, the benefits of statins considerably outweigh the potential risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · cited 1×
“It occurs mainly among patients with other risk factors to develop diabetes (elevated body–mass index, impaired fasting glucose or high HbA1c).(44)”
BackgroundInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Alberts, A. W., Chen, J., Kuron, G., Hunt, V, Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,628
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Lindahl, B., Toss, H., Siegbahn, A., Venge, P., & Wallentin, L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431602 · Cited by 1,224
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Clinical features of sudden obstruction of the coronary arteries
HERRICK, J. B. (1912) · Journal of the American Medical Association · doi:10.1001/jama.1912.04270120001001 · Cited by 908
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 752
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
Statin Use and Reduced Cancer-Related Mortality
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 720
Mammen, A. L., Chung, T., Christopher-Stine, L., Rosen, P., Rosen, A., Doering, K. R., & Casciola-Rosen, L. A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30156 · Cited by 699
Self-citationStatin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1839 · Cited by 683
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
A historical perspective on the discovery of statins
ENDO, A. (2010) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.86.484 · Cited by 548
Lipids and risk of coronary heart disease The Framingham Study
Castelli, W. P., Anderson, K., Wilson, P. W. F., & Levy, D. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90033-m · Cited by 547
The Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
Hippisley-Cox, J., & Coupland, C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 512
Christopher‐Stine, L., Casciola‐Rosen, L. A., Hong, G., Chung, T., Corse, A. M., & Mammen, A. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27572 · Cited by 512
Self-citationRidker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 421
Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
Besseling, J., Kastelein, J. J. P., Defesche, J. C., Hutten, B. A., & Hovingh, G. K. (2015) · JAMA · doi:10.1001/jama.2015.1206 · Cited by 387
Statin-Associated Autoimmune Myopathy
Mammen, A. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515161 · Cited by 366
Self-citationGhirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
Björnsson, E., Jacobsen, E. I., & Kalaitzakis, E. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.023 · Cited by 321
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308
Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1884 · Cited by 293
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
Hanai, J.-I., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32741 · Cited by 281
Werner, J. L., Christopher‐Stine, L., Ghazarian, S. R., Pak, K. S., Kus, J. E., Daya, N. R., Lloyd, T. E., & Mammen, A. L. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34673 · Cited by 255
Self-citationA systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231
Mammen, A. L., Gaudet, D., Brisson, D., Christopher‐Stine, L., Lloyd, T. E., Leffell, M. S., & Zachary, A. A. (2012) · Arthritis Care & Research · doi:10.1002/acr.21671 · Cited by 221
Self-citationOta, H., Eto, M., Kano, M. R., Kahyo, T., Setou, M., Ogawa, S., Iijima, K., Akishita, M., & Ouchi, Y. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.210500 · Cited by 218
Clinical Features of Sudden Obstruction of the Coronary Arteries
HERRICK, J. B. (1983) · JAMA · doi:10.1001/jama.250.13.1757 · Cited by 217
Effect of statins on C-reactive protein in patients with coronary artery disease
Strandberg, T. E., Vanhanen, H., & Tikkanen, M. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)76154-7 · Cited by 209
Lennarz, W. J. (1975) · Science · doi:10.1126/science.167438 · Cited by 195
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
Haynes, R., Lewis, D., Emberson, J., Reith, C., Agodoa, L., Cass, A., Craig, J. C., de Zeeuw, D., Feldt-Rasmussen, B., Fellström, B., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090965 · Cited by 176
Ferrara, D. E., Liu, X., Espinola, R. G., Meroni, P. L., Abukhalaf, I., Harris, E. N., & Pierangeli, S. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11449 · Cited by 144
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I., Frei, C. R., Pugh, M. J., Makris, U., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 129
Statin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Guymer, R. H., Baird, P. N., Varsamidis, M., Busija, L., Dimitrov, P. N., Aung, K. Z., Makeyeva, G. A., Richardson, A. J., Lim, L., & Robman, L. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083759 · Cited by 94
Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome
López-Pedrera, C., Ruiz‐Limón, P., Aguirre, M. A., Barbarroja, N., Pérez‐Sánchez, C., Buendía, P., Rodríguez-García, I. C., Rodríguez‐Ariza, A., Collantes‐Estévez, E., Velasco, F., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135525 · Cited by 92
Statin use and the prevention of venous thromboembolism: a meta-analysis
Agarwal, V., Phung, O. J., Tongbram, V., Bhardwaj, A., & Coleman, C. I. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02439.x · Cited by 77
Legacy of the Framingham Heart Study: Rationale, Design, Initial Findings, and Implications
Wong, N. D., & Levy, D. A. (2013) · Global Heart · doi:10.1016/j.gheart.2012.12.001 · Cited by 50
Sahebkar, A., Catena, C., Ray, K. K., Vallejo‐Vaz, A. J., Reiner, Ž., Sechi, L. A., & Colussi, G. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-10-0770 · Cited by 45
Ueshima, K., Itoh, H., Kanazawa, N., Komuro, I., Nagai, R., Takeuchi, M., Yamazaki, T., & for the EMPATHY study group (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33563 · Cited by 33
Stanley, F. M., Linder, K. M., & Cardozo, T. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138097 · Cited by 9
Cited by
Peña-Jorquera, H., Cid-Jofré, V., Landaeta-Díaz, L., Petermann-Rocha, F., Martorell, M., Zbinden-Foncea, H., Ferrari, G., Jorquera-Aguilera, C., & Cristi-Montero, C. (2023) · Nutrients · doi:10.3390/nu15143244 · Cited by 103
Montelione, N., Loreni, F., Nenna, A., Catanese, V., Scurto, L., Ferrisi, C., Jawabra, M., Gabellini, T., Codispoti, F. A., Spinelli, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030798 · Cited by 30
Yang, L. L., Stiernborg, M., Skott, E., Söderström, Å., Giacobini, M., & Lavebratt, C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.005 · Cited by 29
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Metadata
- Authors
- Pinal-Fernandez, I., Casal-Dominguez, M., & Mammen, A. L.
- Venue
- Medicina Clínica
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 150
- Issue
- 10
- Pages
- 398-402
- ISSN
- 0025-7753 (ISSN-L)
- OpenAlex
- W2776306725
- Cited by
- 171
- References
- 62
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.